QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SNDX

QT59Syndax Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
19.00
-0.04-0.21%
OverviewShort InterestFilings
SNDXQT59Syndax Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
19.00-0.21%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.80
Insider Own8.07%
Shs Outstand88.61M
Perf Week6.09%
Market Cap1.69BForward P/E-EPS next Y-0.67Insider Trans-0.02%Shs Float-Perf Month-1.86%
Enterprise Value1.90BPEG-EPS next Q-0.45Inst Own-Short Float-Perf Quarter-20.83%
Income-248852324.00P/S7.77EPS this Y36.49%Inst Trans-Short Ratio-Perf Half Y-8.30%
Sales217.17MP/B39.62EPS next Y62.33%ROA-51.46%Short Interest-Perf YTD-9.57%
Book/sh0.47P/C-EPS next 5Y-ROE-256.66%52W High25.59 -25.75%Perf Year97.10%
Cash/sh3.97P/FCF-EPS past 3/5Y-ROIC-57.76%52W Low8.59 121.19%Perf 3Y-
Dividend Est.-EV/EBITDA-11.70Sales past 3/5Y- 143.72%Gross Margin97.96%Volatility3.11% 3.34%Perf 5Y-
Dividend TTM-EV/Sales8.76EPS Y/Y TTM25.20%Oper. Margin-102.93%ATR (14)0.86Perf 10Y-
Dividend Ex-Date-Quick Ratio5.06Sales Y/Y TTM804.17%Profit Margin-112.01%RSI (14)48.98Recom2.00
Dividend Gr. 3/5Y-Current Ratio5.47EPS Q/Q51.02%SMA201.89%Beta0.69Target Price38.50
Payout0.00%Debt/Eq8.30Sales Q/Q225.00%SMA50-7.15%Rel Volume2.29Prev Close19.04
Employees270LT Debt/Eq5.32EarningsAug 03SMA200-2.54%Avg Volume1.74MPrice19.00
IPO DateMar 02, 2016Option/ShortYes / YesEPS/Sales Surpr.18.64% -7.14%Net Debt/EBITDA-1.32Volume3,994,857Change-0.21%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-12-26ReiteratedGuggenheimBuy$34 → $31
Jun-03-26ReiteratedH.C. WainwrightBuy$33 → $40
May-04-26ReiteratedStifel Nicolaus$45 → $46
May-01-26ReiteratedBarclaysOverweight$35 → $37
Feb-27-26ReiteratedStifel Nicolaus$44 → $45
Nov-24-25ReiteratedBarclaysOverweight$22 → $35
Nov-04-25ReiteratedBarclaysOverweight$33 → $22
Nov-04-25ReiteratedUBSBuy$35 → $38
Sep-10-25ResumedStifelBuy$44
Jul-15-25ReiteratedUBSBuy$37 → $35
Latest News
Jun-12-26
Jun-12-2608:16AM
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price TargetBenzinga
Jun-11-26
Jun-11-2608:57AM
Syndax Pharmaceuticals: The Duration Expansion Story Is Being UnderpricedSeekingAlpha
08:57AM
Syndax Pharmaceuticals: The Duration Expansion Story Is Being UnderpricedSeekingAlpha
07:11AM
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 CongressBenzinga
07:11AM
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 CongressBenzinga
07:09AM
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical OncologyBenzinga
07:09AM
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical OncologyBenzinga
Jun-10-26
Jun-10-2601:12PM
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue21717224
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A471
Gross Profit21316523
Selling, General and Administrative Excl. Other177180121
Research and Development256259242
Other Operating Expense3-10
Operating Income-223-273-340
Interest Expense81345
Unusual Expense
———
Non-Operating Income (Expense)-60-21-26
Net Income Before Taxes-244-285-319
Income Taxes
000
Consolidated Net Income-244-285-319
Net Income From Continuing Operations-244-285-319
Net Income-244-285-319
EPS (Recurring)-2.80-3.29-3.73
EPS (Basic, Before Extraordinaries)-2.80-3.29-3.73
EPS (Diluted)-2.80-3.29-3.73
EBITDA-162-252-314
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio7.6210.63—
Gross Margin98.1695.9395.83
Operating Margin-102.76-158.72-1,416.67
Net Margin-112.44-165.70-1,329.17
Shares Outstanding878786
Market Capitalization1,6531,828—
Operating Lease Expense
———
Insider Trading Volume
$21.00$20.03$19.06$18.09$17.12● Close Price0.00M0.65M1.29M1.94M2.58MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Option Exercise13.8262,470863,33692,120Jun 12 12:00 AM
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Sale18.1431,235566,60360,885Jun 12 12:00 AM
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Option Exercise13.8222,515311,15795,165Jun 12 12:00 AM
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Sale18.0034,280617,04060,885Jun 12 12:00 AM
Metzger Michael AChief Executive OfficerJun 01 '26Sale18.996,847130,025484,843Jun 02 12:00 AM
Goldan Keith A.Chief Financial OfficerJun 01 '26Sale18.991,17722,351139,252Jun 02 12:00 AM
Metzger Michael AChief Executive OfficerFeb 09 '26Sale21.0317,159360,819491,690Feb 10 12:00 AM
Goldan Keith A.Chief Financial OfficerFeb 09 '26Sale21.033,41071,705140,429Feb 10 12:00 AM
Goldan Keith A.Chief Financial OfficerFeb 06 '26Sale20.622,08242,931143,839Feb 06 12:00 AM
Metzger Michael AChief Executive OfficerFeb 06 '26Sale20.627,412152,835508,849Feb 06 12:00 AM
Metzger Michael AChief Executive OfficerSep 08 '25Option Exercise10.90314,6143,429,292455,968Sep 08 12:00 AM
Metzger Michael AChief Executive OfficerSep 08 '25Sale16.41157,3072,582,021298,661Sep 08 12:00 AM
Podlesak DennisDirectorAug 18 '25Option Exercise7.2038,400276,480210,963Aug 18 12:00 AM
Podlesak DennisDirectorAug 18 '25Sale15.8419,200304,170191,763Aug 18 12:00 AM
Podlesak DennisDirectorAug 15 '25Sale15.5419,200298,408191,763Aug 18 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR